1. Introduction {#sec1}
===============

Alzheimer\'s disease (AD), a progressive neurodegenerative disorder, is responsible for the majority cases of dementia in the elderly population, and it appears in both familial and sporadic forms ([@bib4]). More than 95% of AD subjects suffer from the sporadic form of the disease which has an uncertain etiology involving multiple genetic, metabolic and environmental risk factors ([@bib4]; [@bib24]). It is generally accepted now that the complex pathogenesis of this disease could not possibly be explained solely by Amyloid Cascade Hypothesis which posits that the toxic actions of misfolded and oligomerized amyloid beta peptide (Aβ42) is the driving force of AD pathogenesis ([@bib14]; [@bib27]). This has resulted in the development of several non-transgenic toxin-based animal models in which a gradual development of AD like pathology occurs in the brain along with memory and behavioral deficits. These models are yet to be fully characterized and evaluated, but they show several typical molecular signatures of AD pathogenesis like oxidative damage, neuroinflammation, mitochondrial dysfunction, decreased glucose utilization, altered tau phosphorylation and amyloid beta metabolism in the brain in varying combinations ([@bib12]; [@bib22]). Thus, ICV administration of streptozotocin (STZ) to rodents has been shown in multiple studies to replicate many features of AD pathogenesis at the cellular level both in the cortex and hippocampus along with memory and behavioral deficits, and these changes appear slowly and persist over a long period of time ([@bib6]; [@bib7]; [@bib25]; [@bib10]; [@bib12]; [@bib17]). Although STZ-induced AD model has been suggested as a good tool to understand sporadic AD, the mechanisms of brain-specific toxic actions of STZ remains somewhat conjectural and controversial despite intensive studies ([@bib12]; [@bib17]). Furthermore, the chronological development of different damage mechanisms and their interactions in the brain after administration of ICV-STZ have not been established with certainty, because different groups have reported the brain STZ-effects at different time points after ICV - administration ([@bib5]; [@bib7]; [@bib25]; [@bib8]; [@bib13]; [@bib28]). One important variability is the changes in body-weight of the animals after ICV-STZ administration which has been variously reported in the literature as a loss in body-weight or no changes or an initial loss followed by a gain in body-weight ([@bib2]; [@bib6]; [@bib20]; [@bib23]). However, it is not known if the variability of body-weight changes after ICV-STZ treatment has any effect on the toxic effects STZ in rat brain. Because of the central importance of mitochondrial dysfunction in AD neurodegeneration, we thought it prudent to examine if brain mitochondrial bioenergetic alterations caused by ICV-STZ treatment of rats show variability with the pattern of body-weight loss.

2. Materials and methods {#sec2}
========================

2.1. Materials {#sec2.1}
--------------

Streptozotocin, cytochrome c from equine heart, antimycin A, rotenone, bovine serum albumin, hexokinase were purchased from Sigma-Aldrich, St. Louis, USA. Pyruvic acid sodium salt, sodium succinate, ADP-disodum salt, β-NADH disodium salt, ammonium molybdate, sucrose, EDTA, digitonin, etc. were obtained from Sisco Research Laboratory, Mumbai, India. BCA protein assay kit was from Thermo Fisher Scientific, Waltham, USA. All common reagents and buffers were from HiMedia, Mumbai, India.

2.2. Animals {#sec2.2}
------------

Adult Wistar rats (6--8 months old) of both sexes were randomized and kept as control and experimental groups. The animals were kept in polypropylene cages and fed commercial rat chow with water *ad libitum* under 12 h day/night cycle at a room temperature of 25° ± 1° as per the guidelines of the Institutional Animal Ethics Committee (IAEC) which has also approved the experimental protocols and treatments of the animals for this study.

2.3. Intracerebroventricular administration of streptozotocin {#sec2.3}
-------------------------------------------------------------

The animal was anaesthesized with an intra-peritoneal injection of a combination of ketamine (80 mg/kg body-weight) and xylazine (10 mg/kg body-weight) and the head was positioned on the stereotaxic apparatus and secured with ear bars and the tooth bar. After removing the fur from the top of the skull and thorough cleaning with 70% alcohol, a midline sagittal incision was made, the skin retracted, the wound cleaned of blood and the bregma identified. Following the stereotaxic co-ordinates, two holes were drilled on the skull 0.9 mm caudal and 1.5 mm lateral from the bregma on either side of the sagittal suture. The stereotaxic guide cannula was introduced through either hole 4 mm ventral from the brain surface to reach the lateral ventricle. A freshly prepared solution of STZ (3 mg/kg body-weight) in citrate buffer, pH 4.5 was manually injected in a volume of 4 μl through each hole with the help of a Hamilton syringe connected with the stereotaxic guide cannula. The injection was given slowly over a period of 8 min and the cannula left in place for another 5 min before withdrawal. The skin incision was sutured, an antibiotic ointment applied and the animal allowed to recover. The control rats were similarly administered citrate buffer, pH 4.5.

The body-weights of animals were noted regularly pre- and post-ICV-STZ treatment. The animals were sacrificed on day15 following ICV-STZ treatment and brain mitochondria were analyzed for several bioenergetic parameters. The animals were sacrificed in pairs of control and ICV-STZ-treated rats of same sex on a particular day of experimentation. For validation of ICV administration by stereotaxic method, we performed 4 initial experiments where methylene blue was introduced in to lateral ventricles of rats followed by immediate sacrifice of the animals, decapitation, removal of the brain and macroscopic verification of methylene blue in the lateral ventricles.

2.4. Isolation of rat brain mitochondria {#sec2.4}
----------------------------------------

The animals were sacrificed by cervical dislocation followed by decapitation. The brains were removed and cerebral cortices cleanly dissected out. Mitochondria were isolated from the cortical tissue by differential centrifugation and digitonin treatment as published earlier ([@bib16]). The final mitochondrial pellet was suspended in isotonic buffer A (145 mM KCl, 50 mM sucrose, 5 mM NaCl, 1 mM EGTA, 1 mM MgCl~2~, 10 mM phosphate buffer, pH 7.4) or in 50 mM phosphate buffer, pH 7.4 depending on subsequent experimental protocol.

2.5. Measurement of mitochondrial functional parameters {#sec2.5}
-------------------------------------------------------

Aliquots of freshly prepared mitochondria suspended in isotonic buffer A were used for the measurement of phosphorylation capacity (inorganic phosphate utilization) in the presence of pyruvate (5 mM), succinate (10 mM) and ADP (0.5 mM) as described in our earlier studies ([@bib1]).

For the assay of respiratory complexes, the mitochondrial pellet suspended in 50 mM phosphate buffer and kept frozen at -20 °C was analyzed within 2--3 days. An aliquot of mitochondrial suspension was diluted suitably in 10 mM phosphate buffer, pH 7.4 followed by 3 cycles of freeze-thawing and then used for the assay. Mitochondrial complex I-III activity was determined spectrophotometrically by monitoring the reduction of ferricytochrome c (0.1 mM) at 550 nm in a reaction mixture containing 50 mM phosphate buffer, pH 7.4. 0.01 mM EDTA, 0.25 mM NADH, 5 mM sodium azide with or without rotenone (10 μM) after addition of an appropriate amount of lysed mitochondrial preparation as adapted from a published procedure ([@bib1]). The complex II-III activity was similarly assayed by monitoring the pyruvate-supported reduction of ferricytochrome c based on a published procedure ([@bib1]). Briefly, the reduction of ferricytochrome c (0.6 mg/ml) was monitored at 550 nm in 50 mM phosphate buffer containing succinate (2 mM), EDTA (0.3 mM) and sodium azide (5 mM) in the absence or presence of antimycin A (10 μM). Antimycin A sensitive activity was used to calculate the value of complex II-III.

2.6. Protein estimation {#sec2.6}
-----------------------

Protein in mitochondrial samples was estimated by using a commercial BCA protein assay kit.

2.7. Statistical analysis {#sec2.7}
-------------------------

The distribution of data for normality was checked by Shapiro-Wilk test. For data with normal distribution, the comparison among more than two groups was made by repeated measures one-way ANOVA followed by Bonferroni post test. When the values were not normally distributed and experimental values expressed as the percentage of matched controls, comparisons among multiple groups were made by Kruskal-Wallis test followed by Dunn\'s test, and comparisons between two groups were performed by Wilcoxon Matched-Pairs Signed Rank test to obtain statistical significance. A p value of \<0.05 was accepted to indicate statistical significance.

3. Results {#sec3}
==========

3.1. Changes in body-weight after ICV-STZ {#sec3.1}
-----------------------------------------

When we analyzed the body-weight changes for 15 days following ICV-STZ treatment, some clear variations were seen. The line diagram in [Figure 1](#fig1){ref-type="fig"}A indicates that in some animals moderate to severe loss of body-weights occurred, while in others only minimal changes could be seen. Thus, in Group 1 (GR 1) rats a body-weight loss up to 10% occurred, while Group 2 (GR 2) animals showed weight-loss from above 10% to about 35% ([Figure 1](#fig1){ref-type="fig"}A). [Figure 1](#fig1){ref-type="fig"}B presents the individual data points (body-weights) in different groups as bar-graphs. We checked the plasma glucose levels by glucose oxidase-peroxidase method using commercial kits in control and ICV-STZ treated rats on day 15, but no significant difference was observed in this parameter among different groups (data not shown).Figure 1Body-weight loss after ICV-STZ administration in rats. The body-weights of animals control (11) and ICV-STZ treated GR 1 (5 animals with body-weight loss up to 10%) and GR 2 (6 animals with body-weight loss more than 10% to nearly 35%) were measured on day 0, day 8 and also on day15. A. Values are presented as the means ± SEM. Statistical comparisons were made by repeated measures one-way Anova followed by Bonferroni Post test. ψ indicates statistical significance p \< 0.01, F = 8.888. B. Individual data points are shown in Control, STZ (GR 1) and STZ (GR 2) in the bar-graph (median with range).Figure 1

3.2. Effects of ICV-STZ administration on brain respiratory chain complex activities {#sec3.2}
------------------------------------------------------------------------------------

The changes in mitochondrial respiratory chain complex activities in rat brain cortex after ICV-STZ administration are presented in [Figure 2](#fig2){ref-type="fig"} and [Figure 3](#fig3){ref-type="fig"}A and the values with respect to control shown as the medians with range. The changes in mitochondrial complex I-III activity was first compared between the control and ICV-STZ treated groups ([Figure 2](#fig2){ref-type="fig"}A). Our results show that on day 15 after ICV-STZ treatment the brain cortical mitochondria showed a statistically significant decrease (nearly 25%) in complex I-III activity compared to that in control ([Figure 2](#fig2){ref-type="fig"}A). However, when the STZ-effects were compared with respect to control rats in GR 1 (less than 10% body-weight loss after ICV-STZ) and GR 2 (more than 10%--35% weight loss after ICV-STZ) separately, an interesting phenomenon was observed. The decrease in complex I-III activity after STZ-treatment was mild and not statistically significant in GR 1, but in GR 2 ICV-STZ caused a very significant lowering of complex I-III activity ([Figure 2](#fig2){ref-type="fig"}B). The individual data points (complex I-III activity as percentage of control) are presented as bar-graphs in [Figure 2](#fig2){ref-type="fig"}C. When Spearman\'s correlation analysis was done between percentage loss in complex I-III activity and percentage loss in body-weights in ICV-STZ treated group, no strong association (Spearman\'s co-efficient ρ = 0.354) or statistical significance (p = 0.286) could be found (data not shown). When brain cortical mitochondrial complex II-III activities of control and STZ- treated rats (GR 1 and GR 2) were compared, no statistical difference was observed among the groups ([Figure 3](#fig3){ref-type="fig"}A).Figure 2Mitochondrial complex I-III activity in brain cortex after ICV-STZ administration in rats. Mitochondria were isolated from rat brain cortical tissue on day 15 after ICV-STZ treatment followed by the measurement of complex I-III activity as described in Materials and Methods. Animals of same sex were sacrificed on particular dates in pairs of control and experimental, and complex I-III activity of the experimental animal, normalized to per mg protein, was expressed as percentage of the corresponding control rat (taken as100%). Values were expressed as the median with range (min, max); A. Control (11 animals) and STZ-treated (11 animals); statistical comparisons made by Wilcoxon Matched-Pairs Signed Rank test. ∗p \< 0.01 vs Control. B. Control (11 animals) and STZ-treated rats (STZ (GR 1) 5 animals and STZ (GR 2) 6 animals). Statistical comparisons performed with Kruskal-Wallis test followed by Dunn\'s test; statistically significant, ∗p \< 0.01, F = 7.652. C. Individual data points are shown for Control, STZ (GR 1) and STZ (GR 2) animals in the bar-graph (median with range).Figure 2Figure 3Mitochondrial complex II-III activity and phosphorylation capacity in brain of control and ICV-STZ treated rats. Mitochondria were isolated from brain cortical tissue of rats on day 15 after ICV-STZ treatment, sacrificed in pairs of control and treated animals on a given date, followed by the measurement of complex II-III activity (A) and phosphorylation capacity (B) as described in the text. Values are expressed as median with range (min, max) from three groups: Control (11 animals), STZ-treated rats (STZ (GR 1) 5 animals and STZ (GR 2) 6 animals). Statistical comparisons were made with Kruskal-Wallis test followed by Dunn\'s test.Figure 3

3.3. Brain mitochondrial phosphorylation capacity after ICV-STZ treatment {#sec3.3}
-------------------------------------------------------------------------

When isolated cortical mitochondria were incubated *in vitro* with pyruvate, succinate and ADP (state 3 respiration) from control and STZ- treated GR 1 and GR 2 animals, the mitochondrial phosphorylation capacity (an indirect estimate of mitochondrial ATP production) was not statistically different among the three groups ([Figure 3](#fig3){ref-type="fig"}B).

4. Discussion {#sec4}
=============

Many studies have confirmed significant memory deficits with increased production of reactive oxygen species (ROS), accumulation of oxidative damage markers like malonaldehyde and protein carbonyls, depletion of reduced glutathione and decreased activities of antioxidant enzymes in the brain within 2--3 weeks of STZ administration by ICV ([@bib25]; [@bib13]; [@bib15]; [@bib26]; [@bib28]). Neurodegenerative changes with neuronal loss have also been reported as early effects of ICV-STZ administration ([@bib25]; [@bib19]). Although mitochondrial dysfunction is considered as a hallmark signature of AD pathogenesis, ICV-STZ induced brain mitochondrial damage has been investigated to a lesser extent. Nevertheless, the limited studies indicate multiple bioenergetic deficits in rat brain hippocampus and cortex after ICV-STZ treatment which include decreased oxygen uptake, diminished respiratory complex activities, decreased respiratory control ratio, decreased ATP synthesis and a loss in mitochondrial membrane potential ([@bib7]; [@bib8]; [@bib20]; [@bib23]). These results from different studies are not exactly comparable because the toxic effects of STZ on the brain after ICV-administration develop slowly over the weeks, and these studies have analyzed mitochondrial defects at different time points after STZ treatment. In the current study we could observe only moderate decrease in complex I-III activity without any change in complex II-III activity or ATP synthesis on day 15 after ICV-STZ treatment. More importantly, we observed that the decrease in mitochondrial complex I-III activity in brain cortical tissue following ICV-STZ treatment occurred with statistical significance only in those rats showing a conspicuous loss of body-weights (GR 2). However, overall (GR 1 and GR 2 taken together) there was no strong statistical association between the degree of body-weight loss and the extent of decrease in brain complex I-III activity in ICV-STZ treated rats as determined by using Spearman\'s correlation co-efficient. Apparently, this may look paradoxical, but it tends to suggest that the two groups (GR 1 and GR 2) have differential sensitivity to STZ in terms of body-weight loss and loss of complex I-III activity. However, additional experiments would be necessary to explore this possibility and also to establish if loss of mitochondrial complex I-III activity has a causal link with body-weight loss.

It is interesting that there are variable reports of loss of body-weight in rats following ICV-STZ treatment which has not been examined thoroughly in the context of toxic effects of STZ in the brain ([@bib2]; [@bib6]; [@bib20]; [@bib23]; [@bib29]). In our study in ICV-STZ group, the animals showed a variable loss of body-weights, and in some of those rats showing very significant body-weight loss, we noticed a dramatic change in feeding behavior with animals refusing to take food or water. This observation was consistent with another study published earlier ([@bib23]). Further, when given systemically STZ acts as a diabetogenic agent and destroys β cells of the pancreas after gaining entry in to the cells through GLUT2 transporters ([@bib12]; [@bib30]-). In brain GLUT2 transporters are present in certain areas including hypothalamus where these are located in neurons, endothelial cells as well as special type of ependymal cells called tanycytes ([@bib9]; [@bib31]; [@bib32]). GLUT2 transporters in hypothalamus possibly act as glucose sensors and control feeding behavior, thermoregulation as well as glucose homeostasis in peripheral organs ([@bib9]; [@bib32]). Thus, it is plausible that damage to the GLUT2 containing hypothalamic cells by STZ after ICV administration leads to altered feeding behavior and loss of body-weight in rats, but how this happens in some rats but not in others in the current study remains an open question. However, it will be interesting to probe if other toxic effects of ICV-STZ administration on brain reported in the literature such as oxidative stress, decreased cerebral glucose utilization and neuroinflammation also differ in GR 1 and GR 2 rats. The mechanisms of the multiple toxic effects of STZ on brain after ICV administration are largely unknown, but the damage to GLUT2 containing cells in the brain by STZ could play an important role in this process ([@bib12]; [@bib18]; [@bib30]).

It is also interesting to note in the context of our results that moderate inhibition of complex I-III activity has been shown to increase the neuronal AMP content and activation of AMP dependent protein kinase (AMPK) which causes improved bioenergetic performance of mitochondria and reprogramming of neuronal metabolism ([@bib8]). This may partially explain our failure to demonstrate any loss of complex II-III activity or ATP synthesis by mitochondria after ICV-STZ treatment. However, the unaltered mitochondrial phosphorylation capacity in the presence of a decreased complex I-III activity in ICV-STZ treated rats may also arise from the fact that we measured mitochondrial phosphorylation capacity in the presence of pyruvate and succinate which would by-pass the complex I-III and continue mitochondrial respiration and ATP synthesis through complex II-III. Overall this brief study has indicated several complex issues with regard to STZ effects on brain mitochondria, which should be examined more thoroughly in order to understand the suitability of this toxin in developing a model for sporadic AD.
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